Skip to content

#神经

Today 0 items
Oct 15Thu
  1. statnews.com48

    Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’

    Compass Pathways CEO Kabir Nath said the company will take a cautious approach to launching COMP360, its synthetic psilocybin therapy for treatment-resistant depression, saying bad early patient or provider experiences could harm the broader sector. Compass plans to complete a rolling FDA submission this quarter and aims to launch early next year, expecting a REMS and investing in provider training. In Phase 3 trials, roughly a quarter of patients responded after a single dose, rising to about 40% after a second dose three weeks later.

Oct 13Tue
  1. biopharmadive.com47

    Parkinson’s cell therapy developer files to go public

    Aspen Neuroscience, founded in 2018, has filed registration documents to list on the Nasdaq under ticker "ASPE" and would be the first Parkinson's-focused cell therapy developer to go public in the U.S. Its lead therapy sasineprocel, or ANPD001, reprograms a patient's own cells into dopamine-producing neurons and is entering late-stage testing after an early-stage trial. Aspen has raised about $347 million, posted a $62 million net loss in 2025 and nearly $37 million in the first six months of this year, and warned of substantial doubt about its ability to continue as a going concern without substantial additional capital.

Oct 5Mon
  1. biopharmadive.com40

    Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

    The Nobel Prize in Physiology or Medicine went to Peter Hegemann, Georg Nagel and Karl Deisseroth for optogenetics, a light-based method for studying neurons. Alector licensed its preclinical Parkinson's therapy AL050 to Roche's Genentech for $100 million in guaranteed cash and up to $1.17 billion in milestones plus royalties. Separately, the FDA approved Lilly's Jaypirca as a first-line treatment for CLL or SLL patients without a 17p deletion.

    Why it matters: Nobel recognition for optogenetics and a sizeable Roche-Alector brain drug deal matter to neuroscience-focused readers.

  2. biospace.com58

    Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset

    Genentech is paying $100 million upfront for exclusive development and commercialization rights to Alector's preclinical AL050, a blood-brain barrier-crossing glucocerebrosidase enzyme replacement therapy for neurodegenerative diseases including Parkinson's and Alzheimer's, with up to $1.17 billion in milestones plus tiered royalties. Genentech will handle development, regulatory, manufacturing and commercialization, while Alector retains its Alector Brain Carrier platform. The deal extends Alector's cash runway into 2029 and funds its anti-Aβ antibody AL137 and siRNA programs.

Aug 27Thu
  1. biocentury.com57

    With Biohaven deal, SK Biopharma builds epilepsy franchise, takes step toward ‘big biotech’

    SK Biopharmaceuticals is paying Biohaven $350 million up front for an exclusive worldwide license to opakalim (BHV-7000), a late-stage seizure therapy, plus the Kv7 potassium channel platform behind it. The deal adds a program to SK Biopharma's epilepsy franchise behind Xcopri, its partial-onset seizure drug and primary growth product, while refreshing Biohaven's balance sheet. SK Biopharma takes a step toward its goal of becoming a big biotech.

    Why it matters: Large-scale licensing deal that reshapes two companies' epilepsy portfolios.

Aug 21Fri
  1. fiercepharma.com45

    Lundbeck continues neuroscience evolution as CEO keeps company ‘punching above its weight’

    Lundbeck reported first-half sales growth of 16%, led by Rexulti, up 17% at constant currencies to 3.3 billion Danish kroner (nearly $515 million) in major depressive disorder and Alzheimer's disease-associated agitation, and Vyepti, up 46% to 2.9 billion kroner ($447 million) in migraine prevention. CEO Charl van Zyl expects Vyepti peak U.S. sales of $1.1 billion and flagged generic pressure on Abilify Maintena in Canada and Australia in the second half. Late-stage readouts for the epilepsy drug bexicaserin are slated for the fourth quarter of 2026 and the first quarter of 2027.

Aug 17Mon
Aug 15Sat
  1. BioCentury42

    Syndicate backs MapLight, illuminating path forward in schizophrenia: Public Equity Report

    MapLight Therapeutics raised $150 million from a syndicate to continue developing M1/M4 agonist ML-007C-MA in schizophrenia and Alzheimer's disease psychosis, after its stock fell 73% on July 27 when a once-daily dose missed the primary endpoint of the Phase II ZEPHYR trial. The twice-daily dose did show significance, but investors had wanted clearer differentiation from Bristol Myers Squibb's twice-daily Cobenfy xanomeline/trospium. The new funds support further development in both indications.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org